publication date: Aug. 3, 2017

Gastric Cancer

Differences in subtypes may determine prognosis and response to treatment

Molecular classification of the four distinct subtypes of gastric cancer could potentially shape tailored treatment options by helping to predict survival outcomes and patients’ response to chemotherapy.

The study was published in Clinical Cancer Research, a journal of the American Association for Cancer Research and authored by Ju-Seog Lee, an associate professor in the Department of Systems Biology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston.

In 2014, the Cancer Genome Atlas project discovered that there are four molecular subtypes of gastric cancer: Epstein-Barr virus subtype; microsatellite instability subtype; genomically stable subtype; and chromosomal instability subtype.

In order to identify the clinical significance of the four subtypes, Lee and colleagues re-analyzed gene expression data for these subtypes using data from the gastric cancer cohort of the TCGA project.

They used that data to develop prediction models and tested the models in two independent cohorts of 267 and 432 gastric cancer patients in South Korea and MD Anderson.

Overall, they found that the EBV subtype was associated with the best prognosis for both recurrence-free survival and overall survival, and the GS subtype was associated with the worst prognosis.

The MSI subtype was associated with a moderate prognosis. The CIN subtype was also associated with moderate prognosis, but poorer in the South Korean cohort than in the MD Anderson cohort. Lee said this suggests that the CIN subtype may be less homogeneous and therefore harder to characterize.

The study also sought to examine whether specific subtypes of gastric cancer were associated with a clinical benefit from adjuvant chemotherapy. The researchers based this part of the study solely on the MD Anderson cohort, because more than half of … Continue reading CCL July 2017 – Differences in subtypes may determine prognosis and response to treatment

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.